Format

Send to

Choose Destination
Front Endocrinol (Lausanne). 2012 May 29;3:72. doi: 10.3389/fendo.2012.00072. eCollection 2012.

Prostate cancer - a biomarker perspective.

Author information

1
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA.

Abstract

Despite early detection and reduced risk of death, prostate cancer still remains the second leading cause of cancer death in American men. There is currently no cure for advanced prostate cancer. The multistage, stochastic and highly heterogeneous nature of prostate cancer, coupled with genetic and epigenetic alterations that occur during disease progression and response to therapy, represent fundamental challenges in our quest to understand and control this complex and prevalent disease. Recent advances in drug development and breakthroughs in omics technologies have renewed our efforts to identify novel biomarkers for prostate cancer prognosis, prediction, and therapeutic response monitoring. In this perspective article, we overview the current status and highlight future prospects of biomarkers for prostate cancer, a disease that affects millions of men worldwide.

KEYWORDS:

biomarker; personalized medicine; prostate cancer

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center